Voloridge Investment Management
APRE icon

Voloridge Investment Management’s Aprea Therapeutics APRE Stock Holding History

Voloridge Investment Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,608
Closed -$743K – 1628
2021
Q2 		$743K Sell
7,608
-7,602
-50% -$702K 0.01% 1343
2021
Q1 		$1.55M Buy
+15,210
New +$1.77M 0.01% 900

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Voloridge Investment Management's APRE Position: Q3 2021 in Review

Voloridge Investment Management sold out of Aprea Therapeutics (APRE) in Q3 2021, closing a stake of 7,608 shares — an estimated $743K sold.

Voloridge Investment Management first reported a position in APRE in Q1 2021 and held it in 2 quarters. The position peaked at $1.55M in Q1 2021. 39 funds tracked by Wall St. Rank hold APRE as of Q3 2021.

  • Voloridge Investment Management reported no remaining Aprea Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Voloridge Investment Management sold 7,608 Aprea Therapeutics shares in Q3 2021, an estimated $743K.
  • Voloridge Investment Management first reported a position in Aprea Therapeutics in Q1 2021 and held it in 2 quarters.
  • Voloridge Investment Management's Aprea Therapeutics position peaked at $1.55M in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2021.

Based on Voloridge Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.